Abstract
Many disorders are manifested by dysfunction of key cell types or their disturbed integration in complex organs. Thereby, adult organ systems often bear restricted self-renewal potential and are incapable of achieving functional regeneration. This underlies the need for novel strategies in the field of cell (re-)programming-based regenerative medicine as well as for drug development in vitro. The regenerative field has been hampered by restricted availability of adult stem cells and the potentially hazardous features of pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs). Moreover, ethical concerns and legal restrictions regarding the generation and use of ESCs still exist. The establishment of direct reprogramming protocols for various therapeutically valuable somatic cell types has overcome some of these limitations. Meanwhile, new perspectives for safe and efficient generation of different specified somatic cell types have emerged from numerous approaches relying on exogenous expression of lineage-specific transcription factors, coding and noncoding RNAs, and chemical compounds.
It should be of highest priority to develop protocols for the production of mature and physiologically functional cells with properties ideally matching those of their endogenous counterparts. Their availability can bring together basic research, drug screening, safety testing, and ultimately clinical trials. Here, we highlight the remarkable successes in cellular (re-)programming, which have greatly advanced the field of regenerative medicine in recent years. In particular, we review recent progress on the generation of cardiomyocyte subtypes, with a focus on cardiac pacemaker cells.
Abbreviations
- (±)-BayK-8644:
-
Ca2+ channel agonist
- A83-01:
-
TGF-β inhibitor
- AA:
-
Ascorbic acid
- ACTN2:
-
α-Actinin
- ADSC:
-
Adipose tissue-derived mesenchymal stem cell
- AFP:
-
α-Fetoprotein
- Akt1:
-
AKT serine/threonine kinase 1
- ALB:
-
Albumin
- ALK5:
-
TGFβ type I receptor kinase
- ALP:
-
Alkaline phosphatase
- ANF:
-
NPPA, natriuretic peptide A
- APD:
-
Action potential duration
- APOA1:
-
Apolipoprotein A1
- AS8351:
-
Iron chelator
- ASC:
-
Adult stem cell
- Ascl1:
-
Achaete-scute homolog 1
- ATF5:
-
Activating transcription factor 5
- ATSC:
-
Adipose tissue-derived mesenchymal stem cells
- AV:
-
Atrioventricular
- Bcl2:
-
B-cell lymphoma 2
- BCT:
-
Bioartificial cardiac tissue
- bFGF:
-
Basic fibroblast growth factor
- bHLH:
-
Basic helix-loop-helix
- BIO:
-
6-Bromoindirubin-3′-oxime, canonical Wnt activator
- BIX01294:
-
Diazepin-quinazolinamine derivative; histone-lysine methyltransferase inhibitor
- Bmi1:
-
BMI1 proto-oncogene, polycomb ring finger
- BM-MSC:
-
Bone marrow-derived mesenchymal stem cell
- bpm:
-
Beats per minute
- Bry:
-
Brachyury
- CD166:
-
ALCAM; activated leukocyte cell adhesion molecule
- CEBPA:
-
CCAAT/enhancer binding protein alpha
- CF:
-
Cardiac fibroblast
- CHD:
-
Congenital heart defect
- CHIR:
-
CHIR99021, GSK-3 inhibitor, Wnt activator
- CM:
-
Cardiomyocyte
- C-MYC:
-
MYC proto-oncogene, bHLH transcription factor
- CPC:
-
Cardiac progenitor cell
- CRM:
-
Cardiac reprogramming medium
- CS:
-
Conduction system
- CT99021:
-
SHH and the GSK3β inhibitor
- cTnI:
-
Troponin I3, cardiac type
- cTnT:
-
Troponin T2, cardiac type
- Cx:
-
Gap junction protein
- CYP:
-
Cytochrome P450
- DAPT:
-
N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl ester
- DCX:
-
Newborn neuron
- DES:
-
Desmin
- DF:
-
Dermal fibroblast
- DFSC:
-
Dental follicular-derived mesenchymal stem cell
- DLX1:
-
Distal-less homeobox
- DMEM/F12:
-
Dulbecco’s modified eagle medium: nutrient mixture F-12
- DMD:
-
Dystrophin
- EAD:
-
Early after depolarizations
- EBIO:
-
1-EBIO; KCa2/3 channel activator
- EGF:
-
Epidermal growth factor
- EPC:
-
Endothelial progenitor cell
- EPDC:
-
Epicardium-derived cell
- ESC:
-
Embryonic stem cell
- FFV:
-
FGF2, FGF10 & VEGF
- FGF:
-
Fibroblast growth factor
- FHF:
-
First heart field
- FLF:
-
Fetal limb fibroblast
- forskolin:
-
Adenylyl cyclase activator
- FOX:
-
Forkhead box
- GABA:
-
Gamma-aminobutyric acid
- GAD67:
-
Glutamate decarboxylase 1
- Gata4:
-
GATA binding protein 4
- GF:
-
Gingival fibroblast
- Glut2:
-
SLC2A2; solute carrier family 2 member 2
- GMT:
-
Gata4, Mef2c & Tbx5
- GMTH:
-
Gata4, Mef2c, Tbx5 & Hand2
- GO6983:
-
PKC inhibitor
- GSK126:
-
Selective EZH2 methyltransferase inhibitor
- Hand2:
-
Heart and neural crest derivatives expressed 2
- HC:
-
Hepatocytes
- hCMVEC:
-
Human cardiac microvascular endothelial cell
- HCN:
-
Hyperpolarization-activated cyclic nucleotide channel
- hEF:
-
Human embryonic fibroblast
- HFF:
-
Human foreskin fibroblast
- hiPSC-ECM:
-
Induced pluripotent stem cell-derived embryonic cardiac myocyte
- HNF:
-
Hepatic nuclear factor
- I-BET151:
-
Bromodomain and extra-terminal domain family inhibitor
- If:
-
Funny current
- iPSC:
-
Induced pluripotent stem cell
- Isl1:
-
ISL LIM homeobox 1
- ISX9:
-
Neurogenesis inducer
- ITS:
-
Insulin-transferrin-selenium
- JAK inhibitor I:
-
Janus-Associated Kinase Inhibitor I
- JNJ10198409:
-
ATP-competitive inhibitor of platelet-derived growth Factor receptor tyrosine kinase
- JNK:
-
C-Jun N-terminal kinases
- KLF4:
-
Kruppel like factor 4
- LDL:
-
Low-density lipoprotein
- LDN193189:
-
BMP4 inhibitor
- LF:
-
Lung fibroblast
- Lhx6:
-
LIM homeobox protein 6
- LIF:
-
Leukemia inhibiting factor, JAK/STAT activator
- LMX1A:
-
LIM homeobox transcription factor 1 alpha
- L-MYC:
-
MYCL proto-oncogene, bHLH transcription factor
- lncRNA:
-
Long noncoding RNA
- LVEF:
-
Left ventricular ejection fraction
- Ly294002:
-
Phosphoinositide 3-kinase (PI3K) inhibitor, TGF-β activator
- MafA:
-
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein A
- Map2:
-
Microtubule-associated protein 2
- MAPK:
-
Mitogen-activated protein kinase 1
- MEF:
-
Mouse embryonic fibroblast
- Mef2c:
-
Myocyte enhancer factor 2C
- MF:
-
Myofibroblast
- Mhc:
-
Myosin heavy chain
- MI:
-
Myocardial infarction
- miR:
-
microRNA
- MLC2v:
-
Myosin, light polypeptide 2, regulatory, cardiac, slow
- MM3-GHT:
-
Combination of Gata4, Hand2, Tbx5, and the fusion gene MM3 between Mef2c and the transactivation domain of MyoD
- MRI:
-
Magnet resonance imaging
- MSC:
-
Mesenchymal stem cell
- MYH3:
-
Embryonic myosin
- MYH6:
-
Myosin heavy chain 6, cardiac muscle, alpha
- MyHC:
-
Myosin heavy chain 6
- MyoD:
-
Myogenic differentiation 1
- MYOG:
-
Myogenin
- MYT1L:
-
Myelin transcription factor 1 like
- N2:
-
Cysteine proteinase inhibitor
- NeuN:
-
Neuronal nuclei
- NeuroD1:
-
Neurogenic differentiation 1
- NEUROD2:
-
Neuronal differentiation 2
- NFF:
-
Neonatal foreskin fibroblast
- NG2:
-
Oligodendrocyte precursor
- Ngn:
-
Neurogenin
- NKX:
-
Homeobox protein
- NMDA:
-
N-Methyl-d-aspartate
- NNCF:
-
Neonatal cardiac fibroblast
- NNF:
-
Neonatal fibroblast
- NRVM:
-
Neonatal rat ventricular myocyte
- NURR1:
-
Nuclear receptor related 1 protein
- OAC2:
-
Oct4-activating compound 2
- OB:
-
Osteoblast
- OC:
-
Osteocyte
- OCT4:
-
POU class 5 homeobox 1
- PC:
-
Pacemaker cell
- PD0325901:
-
MEK1/2 inhibitor
- Pdx1:
-
Insulin promoter factor 1
- pkc:
-
Protein kinase C
- PM:
-
Pacemaker
- PROX1:
-
prospero homeobox 1
- PSC:
-
Pluripotent stem cell
- Purmo:
-
Purmorphamine
- PV:
-
Parvalbumin
- Repsox:
-
Inhibitor of the TGF-β type 1 receptor
- ROCK:
-
Rho-associated protein kinase
- RUNX2:
-
Runt related transcription factor 2
- Ryr2:
-
Ryanodine receptor 2
- SAG:
-
Smoothened agonist
- SAN:
-
Sinoatrial node
- SB431542:
-
TGF-β inhibitor
- SC:
-
Stem cell
- SC1:
-
Pluripotin, dual selective inhibitor of the ERK1 and Ras-GAP signaling pathways
- SCD:
-
Sudden cardiac death
- SCN5A:
-
Sodium channel, voltage-gated, type V, alpha subunit
- SERPINA1:
-
Serpin family A member 1
- SHF:
-
Second heart field
- SHH:
-
Sonic hedgehog
- Shox2:
-
Short stature homeobox 2
- shRNA:
-
Small hairpin RNA
- siRNA:
-
Small interfering RNA
- SIRPA:
-
Signal regulatory protein alpha
- SLC1A2:
-
Solute carrier family 1 member 2
- Sox:
-
Sex determining region Y-box 2
- SP600125:
-
JNK inhibitor
- SR-3677:
-
ROCK inhibitor
- SSS:
-
Sick sinus syndrome
- STAT3:
-
Signal transducer and activator of transcription 3
- SU16F:
-
Platelet-derived growth factor receptor β inhibitor
- SV40:
-
Simian vacuolating virus 40
- Tbx:
-
T-box factor 18
- TF:
-
Transcription factor
- TGF-β:
-
Transforming growth factor-β
- THF:
-
Tertiary heart field
- Tnnt2:
-
Troponin T2, cardiac type
- TTF:
-
Tail tip fibroblast
- TTNPB:
-
Analog of retinoic acid
- TUBB3:
-
β-III-tubulin
- Tuj1:
-
Neuron-specific class III beta-tubulin
- Tzv:
-
Thiazovivin
- UNC0638:
-
Histone methyltransferase inhibitor
- VEGF:
-
Vascular endothelial growth factor
- VGLUT1:
-
Vesicular glutamate transporter 1
- VPA:
-
Valporic acid
- XAV939:
-
Wnt inhibitor
- Y-27632:
-
ROCK inhibitor
- α-MHC:
-
Myosin heavy chain 6
- βMe:
-
β-Mercaptoethanol
References
Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabe-Heider F, Walsh S et al (2009) Evidence for cardiomyocyte renewal in humans. Science 324:98–102
Mollova M, Bersell K, Walsh S, Savla J, Das LT, Park S-Y et al (2013) Cardiomyocyte proliferation contributes to heart growth in young humans. Proc Natl Acad Sci U S A 110:1446–1451
World Health Organization (WHO) The top 10 causes of death 2015. www.who.int/mediacentre/factsheets/fs310/en
Eurotransplant (2015) Annual Report 2015. Eurotransplant International Foundation, Leiden. Available at https://www.eurotransplant.org/cms/mediaobject.php?file=AR_ET_20153.pdf
Jain A, Bansal R (2015) Applications of regenerative medicine in organ transplantation. J Pharm Bioallied Sci 7:188–194
Heidary Rouchi A, Mahdavi-Mazdeh M (2015) Regenerative medicine in organ and tissue transplantation: shortly and practically achievable? Int J Organ Transplant Med 6:93–98
Orlando G, Soker S, Stratta RJ, Atala A (2013) Will regenerative medicine replace transplantation? Cold Spring Harb Perspect Med 3:a015693
Rosen MR, Myerburg RJ, Francis DP, Cole GD, Marbán E (2014) Translating stem cell research to cardiac disease therapies: pitfalls and prospects for improvement. J Am Coll Cardiol 64:922–937
Pavo N, Charwat S, Nyolczas N, Jakab A, Murlasits Z, Bergler-Klein J et al (2014) Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. J Mol Cell Cardiol 75:12–24
Matar AA, Chong JJ (2014) Stem cell therapy for cardiac dysfunction. SpringerPlus 3:440
de Feo D, Merlini A, Laterza C, Martino G (2012) Neural stem cell transplantation in central nervous system disorders: from cell replacement to neuroprotection. Curr Opin Neurol 25:322–333
Mothe AJ, Tator CH (2013) Review of transplantation of neural stem/progenitor cells for spinal cord injury. Int J Dev Neurosci 31:701–713
Stamm C, Kleine H-D, Choi Y-H, Dunkelmann S, Lauffs J-A, Lorenzen B et al (2007) Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies. J Thorac Cardiovasc Surg 133:717–725
Wang Z, Wang L, Su X, Pu J, Jiang M, He B (2017) Rational transplant timing and dose of mesenchymal stromal cells in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Stem Cell Res Ther 8:21
Beck S, Lee B-K, Kim J (2015) Multi-layered global gene regulation in mouse embryonic stem cells. Cell Mol Life Sci 72:199–216
Molofsky AV, Pardal R, Morrison SJ (2004) Diverse mechanisms regulate stem cell self-renewal. Curr Opin Cell Biol 16:700–707
Odorico JS, Kaufman DS, Thomson JA (2001) Multilineage differentiation from human embryonic stem cell lines. Stem Cells (Dayton, Ohio) 19:193–204
Draper JS, Fox V (2003) Human embryonic stem cells: multilineage differentiation and mechanisms of self-renewal. Arch Med Res 34:558–564
Trounson A, DeWitt ND (2016) Pluripotent stem cells progressing to the clinic. Nat Rev Mol Cell Biol 17:194–200
Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663–676
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K et al (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861–872
Segers VFM, Lee RT (2008) Stem-cell therapy for cardiac disease. Nature 451:937–942
Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S et al (2013) Steps toward safe cell therapy using induced pluripotent stem cells. Circ Res 112:523–533
Wesselschmidt RL (2011) The teratoma assay: an in vivo assessment of pluripotency. Methods Mol Biol (Clifton, NJ) 767:231–241
Nelakanti RV, Kooreman NG, Wu JC (2015) Teratoma formation: a tool for monitoring pluripotency in stem cell research. Curr Protoc Stem Cell Biol 32:4A.8.1–4A.817
Kamakura T, Makiyama T, Sasaki K, Yoshida Y, Wuriyanghai Y, Chen J et al (2013) Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. Circ J 77:1307–1314
Panopoulos AD, Ruiz S, Belmonte JCI (2011) iPSCs: induced back to controversy. Cell Stem Cell 8:347–348
Davis RL, Weintraub H, Lassar AB (1987) Expression of a single transfected cDNA converts fibroblasts to myoblasts. Cell Press 51:987–1000
Li X, Liu D, Ma Y, Du X, Jing J, Wang L et al (2017) Direct reprogramming of fibroblasts via a chemically induced XEN-like state. Cell Stem Cell. https://doi.org/10.1016/j.stem.2017.05.019
Heinrich C, Blum R, Gascón S, Masserdotti G, Tripathi P, Sánchez R et al (2010) Directing astroglia from the cerebral cortex into subtype specific functional neurons. PLoS Biol 8:e1000373
Caiazzo M, Dell'Anno MT, Dvoretskova E, Lazarevic D, Taverna S, Leo D et al (2011) Direct generation of functional dopaminergic neurons from mouse and human fibroblasts. Nature 476:224–227
Yoo AS, Sun AX, Li L, Shcheglovitov A, Portmann T, Li Y et al (2011) MicroRNA-mediated conversion of human fibroblasts to neurons. Nature 476:228–231
Guo Z, Zhang L, Wu Z, Chen Y, Wang F, Chen G (2014) In vivo direct reprogramming of reactive glial cells into functional neurons after brain injury and in an Alzheimer’s disease model. Cell Stem Cell 14:188–202
Colasante G, Lignani G, Rubio A, Medrihan L, Yekhlef L, Sessa A et al (2015) Rapid conversion of fibroblasts into functional forebrain GABAergic interneurons by direct genetic reprogramming. Cell Stem Cell 17:719–734
Zhang L, Yin J-C, Yeh H, Ma N-X, Lee G, Chen XA et al (2015) Small molecules efficiently reprogram human astroglial cells into functional neurons. Cell Stem Cell 17:735–747
Li X, Zuo X, Jing J, Ma Y, Wang J, Liu D et al (2015) Small-molecule-driven direct reprogramming of mouse fibroblasts into functional neurons. Cell Stem Cell 17:195–203
Hu W, Qiu B, Guan W, Wang Q, Wang M, Li W et al (2015) Direct conversion of normal and alzheimer?: S disease human fibroblasts into neuronal cells by small molecules. Cell Stem Cell 17:204–212
He S, Guo Y, Zhang Y, Li Y, Feng C, Li X et al (2015) Reprogramming somatic cells to cells with neuronal characteristics by defined medium both in vitro and in vivo. Cell Regen (London, England) 4:12
Di Rivetti Val Cervo P, Romanov RA, Spigolon G, Masini D, Martín-Montañez E, Toledo EM et al (2017) Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat Biotechnol 35:444–452
Huang P, He Z, Ji S, Sun H, Xiang D, Liu C et al (2011) Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature 475:386–389
Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z et al (2014) Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell 14:370–384
Du Y, Wang J, Jia J, Song N, Xiang C, Xu J et al (2014) Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell 14:394–403
Simeonov KP, Uppal H (2014) Direct reprogramming of human fibroblasts to hepatocyte-like cells by synthetic modified mRNAs. PLoS One 9:e100134
Kim J, Kim K-P, Lim KT, Lee SC, Yoon J, Song G et al (2015) Generation of integration-free induced hepatocyte-like cells from mouse fibroblasts. Sci Rep 5:15706
Song G, Pacher M, Balakrishnan A, Yuan Q, Tsay H-C, Yang D et al (2016) Direct reprogramming of hepatic myofibroblasts into hepatocytes in vivo attenuates liver fibrosis. Cell Stem Cell 18:797–808
Rezvani M, Español-Suñer R, Malato Y, Dumont L, Grimm AA, Kienle E et al (2016) In vivo hepatic reprogramming of myofibroblasts with AAV vectors as a therapeutic strategy for liver fibrosis. Cell Stem Cell 18:809–816
Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA (2008) In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 455:627–632
Cavelti-Weder C, Li W, Weir GC, Zhou Q (2014) Direct lineage conversion of pancreatic exocrine to endocrine Beta cells in vivo with defined factors. Methods Mol Biol (Clifton, NJ) 1150:247–262
Banga A, Akinci E, Greder LV, Dutton JR, Slack JMW (2012) In vivo reprogramming of Sox9+ cells in the liver to insulin-secreting ducts. Proc Natl Acad Sci U S A 109:15336–15341
Lemper M, Leuckx G, Heremans Y, German MS, Heimberg H, Bouwens L et al (2015) Reprogramming of human pancreatic exocrine cells to β-like cells. Cell Death Differ 22:1117–1130
Zhu S, Russ HA, Wang X, Zhang M, Ma T, Xu T et al (2016) Human pancreatic beta-like cells converted from fibroblasts. Nat Commun 7:10080
Yang X-F, Ren L-W, Yang L, Deng C-Y, Li F-R (2017) In vivo direct reprogramming of liver cells to insulin producing cells by virus-free overexpression of defined factors. Endocr J 64:291–302
Yamamoto K, Kishida T, Sato Y, Nishioka K, Ejima A, Fujiwara H et al (2015) Direct conversion of human fibroblasts into functional osteoblasts by defined factors. Proc Natl Acad Sci U S A 112:6152–6157
Li Y, Wang Y, Yu J, Ma Z, Bai Q, Wu X et al (2017) Direct conversion of human fibroblasts into osteoblasts and osteocytes with small molecules and a single factor, Runx2. doi: 10.1101/127480
Warren L, Manos PD, Ahfeldt T, Loh Y-H, Li H, Lau F et al (2010) Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7:618–630
Hausburg F, Naß S, Voronina N, Skorska A, Müller P, Steinhoff G et al (2015) Defining optimized properties of modified mRNA to enhance virus- and DNA- independent protein expression in adult stem cells and fibroblasts. Cell Physiol Biochem 35:1360–1371
Bichsel C, Neeld D, Hamazaki T, Chang L-J, Yang L-J, Terada N et al (2013) Direct reprogramming of fibroblasts to myocytes via bacterial injection of MyoD protein. Cell Reprogram 15:117–125
Kim EY, Page P, Dellefave-Castillo LM, McNally EM, Wyatt EJ (2016) Direct reprogramming of urine-derived cells with inducible MyoD for modeling human muscle disease. Skelet Muscle 6:32
Horio F, Sakurai H, Ohsawa Y, Nakano S, Matsukura M, Fujii I (2017) Functional validation and expression analysis of myotubes converted from skin fibroblasts using a simple direct reprogramming strategy. eNeurologicalSci 6:9–15
Ieda M, Fu J-D, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG et al (2010) Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 142:375–386
Chen JX, Krane M, Deutsch M-A, Wang L, Rav-Acha M, Gregoire S et al (2012) Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circ Res 111:50–55
Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L et al (2012) In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 485:593–598
Inagawa K, Miyamoto K, Yamakawa H, Muraoka N, Sadahiro T, Umei T et al (2012) Induction of cardiomyocyte-like cells in infarct hearts by gene transfer of Gata4, Mef2c, and Tbx5. Circ Res 111:1147–1156
Qian L, Berry EC, Fu J-D, Ieda M, Srivastava D (2013) Reprogramming of mouse fibroblasts into cardiomyocyte-like cells in vitro. Nat Protoc 8:1204–1215
Wang L, Liu Z, Yin C, Asfour H, Chen O, Li Y et al (2015) Stoichiometry of Gata4, Mef2c, and Tbx5 influences the efficiency and quality of induced cardiac myocyte reprogramming. Circ Res 116:237–244
Song K, Nam Y-J, Luo X, Qi X, Tan W, Huang GN et al (2012) Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature 485:599–604
Jayawardena TM, Egemnazarov B, Finch EA, Zhang L, Payne JA, Pandya K et al (2012) MicroRNA-mediated in vitro and in vivo direct reprogramming of cardiac fibroblasts to cardiomyocytes. Circ Res 110:1465–1473
Jayawardena T, Mirotsou M, Dzau VJ (2014) Direct reprogramming of cardiac fibroblasts to cardiomyocytes using microRNAs. Methods Mol Biol 1150:263–272
Jayawardena TM, Finch EA, Zhang L, Zhang H, Hodgkinson CP, Pratt RE et al (2015) MicroRNA induced cardiac reprogramming in vivo: evidence for mature cardiac myocytes and improved cardiac function. Circ Res 116:418–424
Nam Y-J, Song K, Luo X, Daniel E, Lambeth K, West K et al (2013) Reprogramming of human fibroblasts toward a cardiac fate. Proc Natl Acad Sci U S A 110:5588–5593
Hirai H, Katoku-Kikyo N, Keirstead SA, Kikyo N (2013) Accelerated direct reprogramming of fibroblasts into cardiomyocyte-like cells with the MyoD transactivation domain. Cardiovasc Res 100:105–113
Hirai H, Kikyo N (2014) Inhibitors of suppressive histone modification promote direct reprogramming of fibroblasts to cardiomyocyte-like cells. Cardiovasc Res 102:188–190
Wang H, Cao N, Spencer CI, Nie B, Ma T, Xu T et al (2014) Small molecules enable cardiac reprogramming of mouse fibroblasts with a single factor, Oct4. Cell Rep 6:951–960
Fu Y, Huang C, Xu X, Gu H, Ye Y, Jiang C et al (2015) Direct reprogramming of mouse fibroblasts into cardiomyocytes with chemical cocktails. Cell Res 25:1013–1024
Zhao Y, Londono P, Cao Y, Sharpe EJ, Proenza C, O'Rourke R et al (2015) High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nat Commun 6:8243
Zhou H, Dickson ME, Kim MS, Bassel-Duby R, Olson EN (2015) Akt1/protein kinase B enhances transcriptional reprogramming of fibroblasts to functional cardiomyocytes. Proc Natl Acad Sci U S A 112:11864–11869
Yamakawa H, Muraoka N, Miyamoto K, Sadahiro T, Isomi M, Haginiwa S et al (2015) Fibroblast growth factors and vascular endothelial growth factor promote cardiac reprogramming under defined conditions. Stem Cell Rep 5:1128–1142
Talkhabi M, Pahlavan S, Aghdami N, Baharvand H (2015) Ascorbic acid promotes the direct conversion of mouse fibroblasts into beating cardiomyocytes. Biochem Biophys Res Commun 463:699–705
Park G, Yoon BS, Kim YS, Choi S-C, Moon J-H, Kwon S et al (2015) Conversion of mouse fibroblasts into cardiomyocyte-like cells using small molecule treatments. Biomaterials 54:201–212
Cao N, Huang Y, Zheng J, Spencer CI, Zhang Y, Fu J-D et al (2016) Conversion of human fibroblasts into functional cardiomyocytes by small molecules. Science (New York, NY) 352:1216–1220
Zhou Y, Wang L, Vaseghi HR, Liu Z, Lu R, Alimohamadi S et al (2016) Bmi1 is a key epigenetic barrier to direct cardiac reprogramming. Cell Stem Cell 18:382–395
Mohamed TMA, Stone NR, Berry EC, Radzinsky E, Huang Y, Pratt K et al (2017) Chemical enhancement of in vitro and in vivo direct cardiac reprogramming. Circulation 135:978–995
Hughes RD, Mitry RR, Dhawan A (2012) Current status of hepatocyte transplantation. Transplantation 93:342–347
Laflamme MA, Murry CE (2011) Heart regeneration. Nature 473:326–335
Bhatia SK (2010) Biomaterials for clinical applications
Whelan RS, Kaplinskiy V, Kitsis RN (2010) Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 72:19–44
Anversa P, Kajstura J (1998) Myocyte cell death in the diseased heart. Circ Res 82:1231–1233
Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL (1994) Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 94:1621–1628
Xia P, Liu Y, Cheng Z (2016) Signaling pathways in cardiac myocyte apoptosis. Biomed Res Int 2016:9583268
Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA et al (2005) Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death. Nature 434:658–662
Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H et al (2005) Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 434:652–658
Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H (1960) Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 70:68–78
Matsui Y, Takagi H, Qu X, Abdellatif M, Sakoda H, Asano T et al (2007) Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res 100:914–922
Takagi H, Matsui Y, Hirotani S, Sakoda H, Asano T, Sadoshima J (2007) AMPK mediates autophagy during myocardial ischemia in vivo. Autophagy 3:405–407
Hamacher-Brady A, Brady NR, Gottlieb RA (2006) Enhancing macroautophagy protects against ischemia/reperfusion injury in cardiac myocytes. J Biol Chem 281:29776–29787
Murry CE, Reinecke H, Pabon LM (2006) Regeneration gaps: observations on stem cells and cardiac repair. J Am Coll Cardiol 47:1777–1785
Laflamme MA, Murry CE (2005) Regenerating the heart. Nat Biotechnol 23:845–856
Hasenfuss G (1998) Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 39:60–76
Frangogiannis NG (2015) Pathophysiology of myocardial infarction. Compr Physiol 5:1841–1875
Richardson WJ, Clarke SA, Quinn TA, Holmes JW (2015) Physiological implications of myocardial scar structure. Compr Physiol 5:1877–1909
Leor J, Palevski D, Amit U, Konfino T (2016) Macrophages and regeneration: lessons from the heart. Semin Cell Dev Biol 58:26–33
Ramos G, Hofmann U, Frantz S (2016) Myocardial fibrosis seen through the lenses of T-cell biology. J Mol Cell Cardiol 92:41–45
Lighthouse JK, Small EM (2016) Transcriptional control of cardiac fibroblast plasticity. J Mol Cell Cardiol 91:52–60
Saez P, Kuhl E (2016) Computational modeling of acute myocardial infarction. Comput Methods Biomech Biomed Eng 19:1107–1115
Cheng B, Chen HC, Chou IW, Tang TWH, Hsieh PCH (2017) Harnessing the early post-injury inflammatory responses for cardiac regeneration. J Biomed Sci 24:7
Ghosh AK, Rai R, Flevaris P, Vaughan DE (2017) Epigenetics in reactive and reparative cardiac fibrogenesis: the promise of epigenetic therapy. J Cell Physiol 232:1941–1956. doi:10.1002/jcp.25699
Turner NA (2016) Inflammatory and fibrotic responses of cardiac fibroblasts to myocardial damage associated molecular patterns (DAMPs). J Mol Cell Cardiol 94:189–200
Chen B, Frangogiannis NG (2017) Immune cells in repair of the infarcted myocardium. Microcirculation 24:e12305. https://doi.org/10.1111/micc.12305
Chistiakov DA, Orekhov AN, Bobryshev YV (2016) The role of cardiac fibroblasts in post-myocardial heart tissue repair. Exp Mol Pathol 101:231–240
Kurose H, Mangmool S (2016) Myofibroblasts and inflammatory cells as players of cardiac fibrosis. Arch Pharm Res 39:1100–1113
Garbern JC, Lee RT (2013) Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12:689–698
Senyo SE, Steinhauser ML, Pizzimenti CL, Yang VK, Cai L, Wang M et al (2013) Mammalian heart renewal by pre-existing cardiomyocytes. Nature 493:433–436
Gao Y, Chu M, Hong J, Shang J, Di X (2014) Hypoxia induces cardiac fibroblast proliferation and phenotypic switch: a role for caveolae and caveolin-1/PTEN mediated pathway. J Thorac Dis 6:1458–1468
Moore-Morris T, Cattaneo P, Puceat M, Evans SM (2016) Origins of cardiac fibroblasts. J Mol Cell Cardiol 91:1–5
Kamps JA, Krenning G (2016) Micromanaging cardiac regeneration: targeted delivery of microRNAs for cardiac repair and regeneration. World J Cardiol 8:163–179
Fu J-D, Rushing SN, Lieu DK, Chan CW, Kong C-W, Geng L et al (2011) Distinct roles of microRNA-1 and -499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One 6:e27417
Wilson KD, Hu S, Venkatasubrahmanyam S, Fu J-D, Sun N, Abilez OJ et al (2010) Dynamic microRNA expression programs during cardiac differentiation of human embryonic stem cells: role for miR-499. Circ Cardiovasc Genet 3:426–435
Zhao Y, Samal E, Srivastava D (2005) Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436:214–220
Liu N, Williams AH, Kim Y, McAnally J, Bezprozvannaya S, Sutherland LB et al (2007) An intragenic MEF2-dependent enhancer directs muscle-specific expression of microRNAs 1 and 133. Proc Natl Acad Sci U S A 104:20844–20849
Qian L, Wythe JD, Liu J, Cartry J, Vogler G, Mohapatra B et al (2011) Tinman/Nkx2-5 acts via miR-1 and upstream of Cdc42 to regulate heart function across species. J Cell Biol 193:1181–1196
Ivey KN, Muth A, Arnold J, King FW, Yeh R-F, Fish JE et al (2008) MicroRNA regulation of cell lineages in mouse and human embryonic stem cells. Cell Stem Cell 2:219–229
Huang F, Tang L, Fang Z-f, Hu X-q, Pan J-y, Zhou S-h (2013) miR-1-mediated induction of cardiogenesis in mesenchymal stem cells via downregulation of Hes-1. BioMed Res Int 2013:216286
Nagalingam RS, Safi HA, Czubryt MP (2016) Gaining myocytes or losing fibroblasts: challenges in cardiac fibroblast reprogramming for infarct repair. J Mol Cell Cardiol 93:108–114
Andrée B, Zweigerdt R (2016) Directing Cardiomyogenic differentiation and Transdifferentiation by ectopic gene expression - direct transition or reprogramming detour? CGT 16:14–20
Karpov AA, Udalova DV, Pliss MG, Galagudza MM (2016) Can the outcomes of mesenchymal stem cell-based therapy for myocardial infarction be improved? Providing weapons and armour to cells. Cell Prolif 50(2):e12316. doi:10.1111/cpr.12316
Yang W, Zheng H, Wang Y, Lian F, Hu Z, Xue S (2015) Nesprin-1 has key roles in the process of mesenchymal stem cell differentiation into cardiomyocyte-like cells in vivo and in vitro. Mol Med Rep 11:133–142
Li P, Zhang L (2015) Exogenous Nkx2.5- or GATA-4-transfected rabbit bone marrow mesenchymal stem cells and myocardial cell co-culture on the treatment of myocardial infarction in rabbits. Mol Med Rep 12:2607–2621
Li J, Zhu K, Wang Y, Zheng J, Guo C, Lai H et al (2015) Combination of IGF1 gene manipulation and 5AZA treatment promotes differentiation of mesenchymal stem cells into cardiomyocyte-like cells. Mol Med Rep 11:815–820
Mohanty S, Bose S, Jain KG, Bhargava B, Airan B (2013) TGFβ1 contributes to cardiomyogenic-like differentiation of human bone marrow mesenchymal stem cells. Int J Cardiol 163:93–99
Feng Y, Yang P, Luo S, Zhang Z, Li H, Zhu P et al (2016) Shox2 influences mesenchymal stem cell fate in a co-culture model in vitro. Mol Med Rep 14:637–642
Yu Z, Zou Y, Fan J, Li C, Ma L (2016) Notch1 is associated with the differentiation of human bone marrow-derived mesenchymal stem cells to cardiomyocytes. Mol Med Rep 14:5065–5071
Hou J, Long H, Zhou C, Zheng S, Wu H, Guo T et al (2017) Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro. Stem Cell Res Ther 8:4
Carvalho PH, Daibert APF, Monteiro BS, Okano BS, Carvalho JL, da Cunha DNQ et al (2013) Diferenciação de células-tronco mesenquimais derivadas do tecido adiposo em cardiomiócitos. Arq Bras Cardiol 100:82–89
Wystrychowski W, Patlolla B, Zhuge Y, Neofytou E, Robbins RC, Beygui RE (2016) Multipotency and cardiomyogenic potential of human adipose-derived stem cells from epicardium, pericardium, and omentum. Stem Cell Res Ther 7:84
Gwak S-J, Bhang SH, Yang HS, Kim S-S, Lee D-H, Lee S-H et al (2009) In vitro cardiomyogenic differentiation of adipose-derived stromal cells using transforming growth factor-beta1. Cell Biochem Funct 27:148–154
Nagata H, Ii M, Kohbayashi E, Hoshiga M, Hanafusa T, Asahi M (2016) Cardiac adipose-derived stem cells exhibit high differentiation potential to cardiovascular cells in C57BL/6 mice. Stem Cells Transl Med 5:141–151
Choi YS, Dusting GJ, Stubbs S, Arunothayaraj S, Han XL, Collas P et al (2010) Differentiation of human adipose-derived stem cells into beating cardiomyocytes. J Cell Mol Med 14:878–889
Takahashi T, Nagai T, Kanda M, Liu M-L, Kondo N, Naito AT et al (2015) Regeneration of the cardiac conduction system by adipose tissue-derived stem cells. Circ J 79:2703–2712
Sung I-Y, Son H-N, Ullah I, Bharti D, Park J-M, Cho Y-C et al (2016) Cardiomyogenic differentiation of human dental follicle-derived stem cells by suberoylanilide hydroxamic acid and their in vivo homing property. Int J Med Sci 13:841–852
Lopez-Ruiz E, Peran M, Picon-Ruiz M, Garcia MA, Carrillo E, Jimenez-Navarro M et al (2014) Cardiomyogenic differentiation potential of human endothelial progenitor cells isolated from patients with myocardial infarction. Cytotherapy 16:1229–1237
Hosoda T, Zheng H, Cabral-da-Silva M, Sanada F, Ide-Iwata N, Ogórek B et al (2011) Human cardiac stem cell differentiation is regulated by a mircrine mechanism. Circulation 123:1287–1296
Goumans M-J, de Boer TP, Smits AM, van Laake LW, van Vliet P, Metz CHG et al (2007) TGF-beta1 induces efficient differentiation of human cardiomyocyte progenitor cells into functional cardiomyocytes in vitro. Stem Cell Res 1:138–149
Sluijter JPG, van Mil A, van Vliet P, Metz CHG, Liu J, Doevendans PA et al (2010) MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells. Arterioscler Thromb Vasc Biol 30:859–868
Avitabile D, Crespi A, Brioschi C, Parente V, Toietta G, Devanna P et al (2011) Human cord blood CD34+ progenitor cells acquire functional cardiac properties through a cell fusion process. Am J Phys Heart Circ Phys 300:H1875–H1884
Freeman BT, Kouris NA, Ogle BM (2015) Tracking fusion of human mesenchymal stem cells after transplantation to the heart. Stem Cells Transl Med 4:685–694
Kempf H, Zweigerdt R (2017) Scalable cardiac differentiation of pluripotent stem cells using specific growth factors and small molecules. Adv Biochem Eng/Biotechnol. https://doi.org/10.1007/10_2017_XX
Yang X, Pabon L, Murry CE (2014) Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res 114:511–523
Veerman CC, Kosmidis G, Mummery CL, Casini S, Verkerk AO, Bellin M (2015) Immaturity of human stem-cell-derived cardiomyocytes in culture: fatal flaw or soluble problem? Stem Cells Dev 24:1035–1052
Bhattacharya S, Burridge PW, Kropp EM, Chuppa SL, Kwok W-M, Wu JC et al (2014) High efficiency differentiation of human pluripotent stem cells to cardiomyocytes and characterization by flow cytometry. J Vis Exp 91:52010
Chen VC, Ye J, Shukla P, Hua G, Chen D, Lin Z et al (2015) Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Res 15:365–375
Protze SI, Liu J, Nussinovitch U, Ohana L, Backx PH, Gepstein L et al (2017) Sinoatrial node cardiomyocytes derived from human pluripotent cells function as a biological pacemaker. Nat Biotechnol 35:56–68
Pei F, Jiang J, Bai S, Cao H, Tian L, Zhao Y et al (2017) Chemical-defined and albumin-free generation of human atrial and ventricular myocytes from human pluripotent stem cells. Stem Cell Res 19:94–103
Fuerstenau-Sharp M, Zimmermann ME, Stark K, Jentsch N, Klingenstein M, Drzymalski M et al (2015) Generation of highly purified human cardiomyocytes from peripheral blood mononuclear cell-derived induced pluripotent stem cells. PLoS One 10:e0126596
Mazzotta S, Neves C, Bonner RJ, Bernardo AS, Docherty K, Hoppler S (2016) Distinctive roles of canonical and noncanonical Wnt signaling in human embryonic cardiomyocyte development. Stem Cell Rep 7:764–776
Kempf H, Olmer R, Kropp C, Rückert M, Jara-Avaca M, Robles-Diaz D et al (2014) Controlling expansion and cardiomyogenic differentiation of human pluripotent stem cells in scalable suspension culture. Stem Cell Rep 3:1132–1146
Kempf H, Olmer R, Haase A, Franke A, Bolesani E, Schwanke K et al (2016) Bulk cell density and Wnt/TGFbeta signalling regulate mesendodermal patterning of human pluripotent stem cells. Nat Commun 7:13602
Chen VC, Couture SM, Ye J, Lin Z, Hua G, Huang H-IP et al (2012) Scalable GMP compliant suspension culture system for human ES cells. Stem Cell Res 8:388–402
Palpant NJ, Pabon L, Friedman CE, Roberts M, Hadland B, Zaunbrecher RJ et al (2017) Generating high-purity cardiac and endothelial derivatives from patterned mesoderm using human pluripotent stem cells. Nat Protoc 12:15–31
Hattori F, Chen H, Yamashita H, Tohyama S, Satoh Y-S, Yuasa S et al (2010) Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 7:61–66
Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, Elefanty AG et al (2011) SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 29:1011–1018
van Hoof D, Dormeyer W, Braam SR, Passier R, Monshouwer-Kloots J, Ward-van Oostwaard D et al (2010) Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. J Proteome Res 9:1610–1618
Uosaki H, Fukushima H, Takeuchi A, Matsuoka S, Nakatsuji N, Yamanaka S et al (2011) Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One 6:e23657
Tohyama S, Hattori F, Sano M, Hishiki T, Nagahata Y, Matsuura T et al (2013) Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12:127–137
Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP et al (2009) Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 104:e30–e41
Pasquier J, Gupta R, Rioult D, Hoarau-Vechot J, Courjaret R, Machaca K et al (2017) Coculturing with endothelial cells promotes in vitro maturation and electrical coupling of human embryonic stem cell-derived cardiomyocytes. J Heart Lung Transplant 36(6):684–693
Kensah G, Roa Lara A, Dahlmann J, Zweigerdt R, Schwanke K, Hegermann J et al (2013) Murine and human pluripotent stem cell-derived cardiac bodies form contractile myocardial tissue in vitro. Eur Heart J 34:1134–1146
Oberwallner B, Brodarac A, Anic P, Saric T, Wassilew K, Neef K et al (2015) Human cardiac extracellular matrix supports myocardial lineage commitment of pluripotent stem cells. Eur J Cardiothorac Surg 47:416–425. discussion 425
Amano Y, Nishiguchi A, Matsusaki M, Iseoka H, Miyagawa S, Sawa Y et al (2016) Development of vascularized iPSC derived 3D-cardiomyocyte tissues by filtration layer-by-layer technique and their application for pharmaceutical assays. Acta Biomater 33:110–121
Valarmathi MT, Fuseler JW, Davis JM, Price RL (2017) A novel human tissue-engineered 3-D functional vascularized cardiac muscle construct. Front Cell Dev Biol 5:2
Eder A, Vollert I, Hansen A, Eschenhagen T (2016) Human engineered heart tissue as a model system for drug testing. Adv Drug Deliv Rev 96:214–224
Kempf H, Andree B, Zweigerdt R (2016) Large-scale production of human pluripotent stem cell derived cardiomyocytes. Adv Drug Deliv Rev 96:18–30
Walsh-Irwin C, Hannibal GB (2015) Sick sinus syndrome. AACN Adv Crit Care 26:376–380
Dobrzynski H, Boyett MR, Anderson RH (2007) New insights into pacemaker activity: promoting understanding of sick sinus syndrome. Circulation 115:1921–1932
Ewy GA (2014) Sick sinus syndrome: synopsis. J Am Coll Cardiol 64:539–540
Semelka M, Gera J, Usman S (2013) Sick sinus syndrome: a review. Am Fam Physician 87:691–696
Gregoratos G (2005) Indications and recommendations for pacemaker therapy. Am Fam Physician 71:1563–1570
Tse G, Liu T, Li KH, Laxton V, Wong AO, Chan YW et al (2017) Tachycardia-bradycardia syndrome: electrophysiological mechanisms and future therapeutic approaches (review). Int J Mol Med 39:519–526
Bakker ML, Boink GJ, Boukens BJ, Verkerk AO, van den Boogaard M, den Haan AD et al (2012) T-box transcription factor TBX3 reprogrammes mature cardiac myocytes into pacemaker-like cells. Cardiovasc Res 94:439–449
Hu Y-F, Dawkins JF, Cho HC, Marban E, Cingolani E (2014) Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med 6:245ra94
Kapoor N, Liang W, Marban E, Cho HC (2013) Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18. Nat Biotechnol 31:54–62
Ionta V, Liang W, Kim EH, Rafie R, Giacomello A, Marban E et al (2015) SHOX2 overexpression favors differentiation of embryonic stem cells into cardiac pacemaker cells, improving biological pacing ability. Stem Cell Rep 4:129–142
Jung JJ, Husse B, Rimmbach C, Krebs S, Stieber J, Steinhoff G et al (2014) Programming and isolation of highly pure physiologically and pharmacologically functional sinus-nodal bodies from pluripotent stem cells. Stem Cell Rep 2:592–605
Lown B (1967) Electrical reversion of cardiac arrhythmias. Br Heart J 29:469–489
Johns DC, Nuss HB, Chiamvimonvat N, Ramza BM, Marban E, Lawrence JH (1995) Adenovirus-mediated expression of a voltage-gated potassium channel in vitro (rat cardiac myocytes) and in vivo (rat liver). A novel strategy for modifying excitability. J Clin Invest 96:1152–1158
Miake J, Marbán E, Nuss HB (2002) Biological pacemaker created by gene transfer. Nature 419:132–133
Schram G (2002) Differential distribution of cardiac ion channel expression as a basis for regional specialization in electrical function. Circ Res 90:939–950
Kubo Y, Baldwin TJ, Jan YN, Jan LY (1993) Primary structure and functional expression of a mouse inward rectifier potassium channel. Nature 362:127–133
Tinker A, Jan YN, Jan LY (1996) Regions responsible for the assembly of inwardly rectifying potassium channels. Cell 87:857–868
Miake J, Marbán E, Nuss HB (2003) Functional role of inward rectifier current in heart probed by Kir2.1 overexpression and dominant-negative suppression. J Clin Invest 111:1529–1536
Brugada P, Wellens HJ (1985) Early afterdepolarizations: role in conduction block, “prolonged repolarization-dependent reexcitation,” and tachyarrhythmias in the human heart. Pacing Clin Electrophysiol 8:889–896
January CT, Moscucci A (1992) Cellular mechanisms of early afterdepolarizations. Ann N Y Acad Sci 644:23–32
Ennis IL, Li RA, Murphy AM, Marbán E, Nuss HB (2002) Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility. J Clin Invest 109:393–400
Baruscotti M, Bucchi A, Difrancesco D (2005) Physiology and pharmacology of the cardiac pacemaker (“funny”) current. Pharmacol Ther 107:59–79
Plotnikov AN, Sosunov EA, Qu J, Shlapakova IN, Anyukhovsky EP, Liu L et al (2004) Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates. Circulation 109:506–512
Qu J, Plotnikov A, Danilo P, Shlapakova I, Cohen IS, Robinson RB et al (2003) Expression and function of a biological pacemaker in canine heart. Circulation 107:1106–1109
Tse H-F, Xue T, Lau C-P, Siu C-W, Wang K, Zhang Q-Y et al (2006) Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN Channel reduces the dependence on electronic pacemaker in a sick-sinus syndrome model. Circulation 114:1000–1011
Kashiwakura Y, Cho HC, Barth AS, Azene E, Marbán E (2006) Gene transfer of a synthetic pacemaker channel into the heart: a novel strategy for biological pacing. Circulation 114:1682–1686
Cho HC, Kashiwakura Y, Marbán E (2007) Creation of a biological pacemaker by cell fusion. Circ Res 100:1112–1115
Dorn T, Goedel A, Lam JT, Haas J, Tian Q, Herrmann F et al (2015) Direct nkx2-5 transcriptional repression of isl1 controls cardiomyocyte subtype identity. Stem Cells (Dayton, Ohio) 33:1113–1129
Frank DU, Carter KL, Thomas KR, Burr RM, Bakker ML, Coetzee WA et al (2012) Lethal arrhythmias in Tbx3-deficient mice reveal extreme dosage sensitivity of cardiac conduction system function and homeostasis. Proc Natl Acad Sci U S A 109:E154–E163
Hoogaars WMH, Engel A, Brons JF, Verkerk AO, de Lange FJ, Wong LYE et al (2007) Tbx3 controls the sinoatrial node gene program and imposes pacemaker function on the atria. Genes Dev 21:1098–1112
Vedantham V, Galang G, Evangelista M, Deo RC, Srivastava D (2015) RNA sequencing of mouse sinoatrial node reveals an upstream regulatory role for islet-1 in cardiac pacemaker cells. Circ Res 116:797–803
Wiese C, Grieskamp T, Airik R, Mommersteeg MTM, Gardiwal A, de Gier-de Vrie C et al (2009) Formation of the sinus node head and differentiation of sinus node myocardium are independently regulated by Tbx18 and Tbx3. Circ Res 104:388–397
Greulich F, Trowe M-O, Leffler A, Stoetzer C, Farin HF, Kispert A (2016) Misexpression of Tbx18 in cardiac chambers of fetal mice interferes with chamber-specific developmental programs but does not induce a pacemaker-like gene signature. J Mol Cell Cardiol 97:140–149
Nam Y-J, Lubczyk C, Bhakta M, Zang T, Fernandez-Perez A, McAnally J et al (2014) Induction of diverse cardiac cell types by reprogramming fibroblasts with cardiac transcription factors. Development 141:4267–4278
Bruzauskaite I, Bironaite D, Bagdonas E, Skeberdis VA, Denkovskij J, Tamulevicius T et al (2016) Relevance of HCN2-expressing human mesenchymal stem cells for the generation of biological pacemakers. Stem Cell Res Ther 7:67
Feng Y, Luo S, Tong S, Zhong L, Zhang C, Yang P et al (2015) Electric-pulse current stimulation increases if current in mShox2 genetically modified canine mesenchymal stem cells. Cardiology 132:49–57
Feng Y, Luo S, Yang P, Song Z (2016) Electric pulse current stimulation increases electrophysiological properties of If current reconstructed in mHCN4-transfected canine mesenchymal stem cells. Exp Ther Med 11:1323–1329
Jun C, Zhihui Z, Lu W, Yaoming N, Lei W, Yao Q et al (2012) Canine bone marrow mesenchymal stromal cells with lentiviral mHCN4 gene transfer create cardiac pacemakers. Cytotherapy 14:529–539
Lu W, Yaoming N, Boli R, Jun C, Changhai Z, Yang Z et al (2013) mHCN4 genetically modified canine mesenchymal stem cells provide biological pacemaking function in complete dogs with atrioventricular block. Pacing Clin Electrophysiol 36:1138–1149
Ma J, Zhang C, Huang S, Wang G, Quan X (2010) Use of rats mesenchymal stem cells modified with mHCN2 gene to create biologic pacemakers. J Huazhong Univ Sci Technol Med Sci 30:447–452
Plotnikov AN, Shlapakova I, Szabolcs MJ, Danilo P, Lorell BH, Potapova IA et al (2007) Xenografted adult human mesenchymal stem cells provide a platform for sustained biological pacemaker function in canine heart. Circulation 116:706–713
Potapova I, Plotnikov A, Lu Z, Danilo P, Valiunas V, Qu J et al (2004) Human mesenchymal stem cells as a gene delivery system to create cardiac pacemakers. Circ Res 94:952–959
Yang J, Song T, Wu P, Chen Y, Fan X, Chen H et al (2012) Differentiation potential of human mesenchymal stem cells derived from adipose tissue and bone marrow to sinus node-like cells. Mol Med Rep 5:108–113
Yang X-J, Zhou Y-F, Li H-X, Han L-H, Jiang W-P (2008) Mesenchymal stem cells as a gene delivery system to create biological pacemaker cells in vitro. J Int Med Res 36:1049–1055
Zhou Y-F, Yang X-J, Li H-X, Han L-H, Jiang W-P (2013) Genetically-engineered mesenchymal stem cells transfected with human HCN1 gene to create cardiac pacemaker cells. J Int Med Res 41:1570–1576
Zhou Y-F, Yang X-J, Li H-X, Han L-H, Jiang W-P (2007) Mesenchymal stem cells transfected with HCN2 genes by LentiV can be modified to be cardiac pacemaker cells. Med Hypotheses 69:1093–1097
Tong M, Yang X-J, Geng B-y, Han L-H, Zhou Y-F, Zhao X et al (2010) Overexpression of connexin 45 in rat mesenchymal stem cells improves the function as cardiac biological pacemakers. Chin Med J 123:1571–1576
Chen L, Deng Z-J, Zhou J-S, Ji R-J, Zhang X, Zhang C-S et al (2017) Tbx18-dependent differentiation of brown adipose tissue-derived stem cells toward cardiac pacemaker cells. Mol Cell Biochem. doi:10.1007/s11010-017-3016-y
Wobus AM, Wallukat G, Hescheler J (1991) Pluripotent mouse embryonic stem cells are able to differentiate into cardiomyocytes expressing chronotropic responses to adrenergic and cholinergic agents and Ca2+ channel blockers. Differentiation 48:173–182
David R, Stieber J, Fischer E, Brunner S, Brenner C, Pfeiler S et al (2009) Forward programming of pluripotent stem cells towards distinct cardiovascular cell types. Cardiovasc Res 84:263–272
Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD et al (2014) Chemically defined generation of human cardiomyocytes. Nat Methods 11:855–860
Hazeltine LB, Badur MG, Lian X, Das A, Han W, Palecek SP (2014) Temporal impact of substrate mechanics on differentiation of human embryonic stem cells to cardiomyocytes. Acta Biomater 10:604–612
Lian X, Hsiao C, Wilson G, Zhu K, Hazeltine LB, Azarin SM et al (2012) Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A 109:E1848–E1857
Ojala M, Rajala K, Pekkanen-Mattila M, Miettinen M, Huhtala H, Aalto-Setala K (2012) Culture conditions affect cardiac differentiation potential of human pluripotent stem cells. PLoS One 7:e48659
Kleger A, Seufferlein T, Malan D, Tischendorf M, Storch A, Wolheim A et al (2010) Modulation of calcium-activated potassium channels induces cardiogenesis of pluripotent stem cells and enrichment of pacemaker-like cells. Circulation 122:1823–1836
Jara-Avaca M, Kempf H, Ruckert M, Robles-Diaz D, Franke A, de La Roche J et al (2017) EBIO does not induce cardiomyogenesis in human pluripotent stem cells but modulates cardiac subtype enrichment by lineage-selective survival. Stem Cell Rep 8:305–317
Scavone A, Capilupo D, Mazzocchi N, Crespi A, Zoia S, Campostrini G et al (2013) Embryonic stem cell-derived CD166+ precursors develop into fully functional sinoatrial-like cells. Circ Res 113:389–398
Rust W, Balakrishnan T, Zweigerdt R (2009) Cardiomyocyte enrichment from human embryonic stem cell cultures by selection of ALCAM surface expression. Regen Med 4:225–237
Hashem SI, Claycomb WC (2013) Genetic isolation of stem cell-derived pacemaker-nodal cardiac myocytes. Mol Cell Biochem 383:161–171
Rimmbach C, Jung JJ, David R (2015) Generation of murine cardiac pacemaker cell aggregates based on ES-cell-programming in combination with Myh6-promoter-selection. J Vis Exp 96:e52465
Wolfien M, Rimmbach C, Schmitz U, Jung JJ, Krebs S, Steinhoff G et al (2016) TRAPLINE: a standardized and automated pipeline for RNA sequencing data analysis, evaluation and annotation. BMC Bioinform 17:21
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Hausburg, F., Jung, J.J., David, R. (2017). Specific Cell (Re-)Programming: Approaches and Perspectives. In: Martin, U., Zweigerdt, R., Gruh, I. (eds) Engineering and Application of Pluripotent Stem Cells. Advances in Biochemical Engineering/Biotechnology, vol 163. Springer, Cham. https://doi.org/10.1007/10_2017_27
Download citation
DOI: https://doi.org/10.1007/10_2017_27
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-73590-0
Online ISBN: 978-3-319-73591-7
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)